Cytek Biosciences, Inc.
No enriched coverage for $CTKB in the last 7 days.
No SEC Form 4 filings for $CTKB in the last 30 days.
See all $CTKB insider activity →Cytek Biosciences (CTKB) reported Q2 2026 revenue of $48.1M, up 6% YoY, with recurring revenue at 35% of total. Gross profit rose 19% to $28.3M, but net loss doubled to $12.2M. Operating expenses increased 15% YoY. Full-year revenue guidance raised to $207M-$212M. Hedge fund ownership rose to 26 funds.
Cytek Biosciences (CTKB) reported Q2 2026 revenue of $48.1M, up 6% Y/Y, driven by the US and China. Service revenue rose to $15.6M, and recurring reagent and service revenue was $18.5M (35% of revenue). Adjusted gross margin was 56% and GAAP net loss was $12.2M. Full-year 2026 guidance is $207M to $212M.
Cytek Biosciences (NASDAQ:CTKB) reported Q2 results on an earnings call. Biopharma, distributors and CRO revenue rose about 22% to $29M, while academic and government revenue fell about 12% to $19.1M. Product revenue increased 4% to $32.6M. Recurring reagent and service revenue was $18.5M (35% of trailing 12-month revenue). GAAP net loss widened to $12.2M. Cytek raised 2026 revenue guidance to $207M-$212M and launched the Borealis 60-color cytometer.
Recent CTKB coverage spans earnings, financial news and corporate actions.
Mixed results: revenue growth supports upside, widening losses and negative adjusted EBITDA pressure downside.
CTKB’s earnings call provides fresh operating metrics (revenue mix, margins, cash) plus an updated full-year revenue range, with a clear regional headwind in EMEA.
Raised full-year revenue guidance and highlighted accelerating recurring revenue and new high-end instrument launches, likely supporting a positive near-term sentiment bias.
The filing provides fresh quarterly performance and a raised revenue outlook, with recurring revenue and installed-base growth as the key drivers.
The facility is a tangible investment in R&D and customer-facing capabilities, but the article provides no financial targets or near-term guidance impact.
AlphAI scores every news story that mentions CTKB with an AI model for sentiment and relevance, and aggregates insider trades from Cytek Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Cytek Biosciences (CTKB) reported Q2 2026 revenue of $48.1M, up 6% YoY, with recurring revenue at 35% of total. Gross profit rose 19% to $28.3M, but net loss doubled to $12.2M. Operating expenses increased 15% YoY. Full-year revenue guidance raised to $207M-$212M. Hedge fund ownership rose to 26 funds.
3 min readCytek Biosciences (CTKB) reported Q2 2026 revenue of $48.1M, up 6% Y/Y, driven by the US and China. Service revenue rose to $15.6M, and recurring reagent and service revenue was $18.5M (35% of revenue). Adjusted gross margin was 56% and GAAP net loss was $12.2M. Full-year 2026 guidance is $207M to $212M.
6 min readCytek Biosciences (NASDAQ:CTKB) reported Q2 results on an earnings call. Biopharma, distributors and CRO revenue rose about 22% to $29M, while academic and government revenue fell about 12% to $19.1M. Product revenue increased 4% to $32.6M. Recurring reagent and service revenue was $18.5M (35% of trailing 12-month revenue). GAAP net loss widened to $12.2M. Cytek raised 2026 revenue guidance to $207M-$212M and launched the Borealis 60-color cytometer.
4 min readCytek Biosciences, Inc. (CTKB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cytek Biosciences Reports Second Quarter 2026 Financial Results FREMONT, Calif., August 5, 2026 (GLOBE NEWSWIRE) – Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for
6 min readCytek Biosciences (Nasdaq: CTKB) said it opened a new innovation center in Bellevue, Washington, relocating its Seattle-area operations. The facility is designed as a sole-tenant hub for R&D labs, instrument service training, customer demonstrations, and assembly and testing. CEO Wenbin Jiang said it supports development and delivery of new technologies and customer engagement.
3 min readCytek Biosciences, Inc. (CTKB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001831915 0001831915 2026-07-09 2026-07-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2
2 min readCytek Biosciences, Inc. (CTKB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001831915 0001831915 2026-06-18 2026-06-18 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18,
3 min readCytek Biosciences, Inc. (CTKB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001831915 0001831915 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
2 min readCytek Biosciences, Inc. (CTKB) released its Q1 2026 earnings, reporting an EPS of -$0.10, missing estimates by $0.02, and revenue of $44.14M, a 6.46% year-over-year increase but still missing estimates by $165.00K. This article provides access to the slide deck published in conjunction with their earnings call.
4 min readImage source: The Motley Fool.Wednesday, November 5, 2025 at 4:30 p.m. ETChief Executive Officer - Wenbin JiangContinue reading ...
5 min read
